Pioglitazone Ameliorates Mitochondrial Oxidative Stress and Inflammation via AMPK-Dependent Inhibition of Mitochondrial Fission in Leigh Syndrome

Abstract

Loss of function mutations of NDUFS4 resulted in Leigh syndrome, which is a progressive neurodegenerative disease and characterized by mitochondrial oxidative stress, inflammation and aberrant mitochondrial dynamics. However, there is currently no effective treatment. Here, we demonstrate that pioglitazone significantly mitigates mitochondrial reactive oxygen species (ROS) generation, lowers cyclooxygenase-2 (COX-2) mRNA levels, and rescues aberrant mitochondrial dynamics in vitro (increasing Opa-1 expression while decreasing Drp-1 expression). Furthermore, similar effects were observed with the selective Drp-1 inhibitor mdivi-1, suggesting that inhibiting mitochondrial fission mediates the therapeutic effects of pioglitazone. Pioglitazone administration activated AMPK phosphorylation, but these effects, along with pioglitazone's ability to reverse oxidative stress, inflammation, and mitochondrial fission, were abolished by the AMPK inhibitor compound C. In vivo, pioglitazone alleviated motor dysfunction, prolonged lifespan, and promoted weight gain in Ndufs4 KO mice. This was accompanied by enhanced mitochondrial fusion and increased levels of mitochondrial complex subunits. Consistently, pioglitazone attenuated neuroinflammation and oxidative stress in vivo. Collectively, our findings indicate that pioglitazone alleviates mitochondrial oxidative stress and inflammation through an AMPK-dependent inhibition of Drp-1-mediated mitochondrial fission. Therefore, suppression of mitochondrial fission may represent a novel therapeutic strategy for Leigh syndrome (LS).

References

[1] N. J. Lake, M. J. Bird, P. Isohanni, and A. Paetau, “Leigh Syndrome: Neuropathology and Pathogenesis,” Journal of Neuropathology and Experimental Neurology 74, no. 6 (2015): 482–492.

[2] L. Chen, Y. Cui, D. Jiang, et al., “Management of Leigh Syndrome: Current Status and New Insights,” Clinical Genetics 93, no. 6 (2018): 1131–1140.

[3] J. Carroll, I. M. Fearnley, J. M. Skehel, R. J. Shannon, J. Hirst, and J. E. Walker, “Bovine Complex I Is a Complex of 45 Different Subunits,” Journal of Biological Chemistry 281, no. 43 (2006): 32724–32727.

[4] S. E. Kruse, W. C. Watt, D. J. Marcinek, R. P. Kapur, K. A. Schenkman, and R. D. Palmiter, “Mice With Mitochondrial Complex I Deficiency Develop a Fatal Encephalomyopathy,” Cell Metabolism 7, no. 4 (2008): 312–320.

[5] A. Quintana, S. Kruse, R. P. Kapur, et al., “Complex I Deficiency due to Loss of Ndufs4 in the Brain Results in Progressive Encephalopathy Resembling Leigh Syndrome,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 24 (2010): 10996–11001.

[6] A. Quintana, S. Zanella, H. Koch, et al., “Fatal Breathing Dysfunction in a Mouse Model of Leigh Syndrome,” Journal of Clinical Investigation 122, no. 7 (2012): 2359–2368.

[7] Y. Kushnareva, A. N. Murphy, and A. Andreyev, “Complex I-Mediated Reactive Oxygen Species Generation: Modulation by Cytochrome c and NAD(P)+ Oxidation-Reduction State,” Biochemical Journal 368, no. Pt 2 (2002): 545–553.

[8] A. P. West and G. Shadel, “Mitochondria in Innate Immune Responses,” Nature Reviews Immunology 11, no. 6 (2011): 389–402.

[9] G. Civiletto, T. Varanita, R. Cerutti, et al., “Opa1 Overexpression Ameliorates the Phenotype of Two Mitochondrial Disease Mouse Models,” Cell Metabolism 21, no. 6 (2015): 845–854.

[10] B. Westermann, “Mitochondrial Fusion and Fission in Cell Life and Death,” Nature Reviews. Molecular Cell Biology 11, no. 12 (2010): 872–884.

[11] K. Itoh, K. Nakamura, M. Iijima, and H. Sesaki, “Mitochondrial Dynamics in Neurodegeneration,” Trends in Cell Biology 23, no. 2 (2013): 64–71.

[12] S. Cogliati, C. Frezza, M. E. Soriano, et al., “Mitochondrial Cristae Shape Determines Respiratory Chain Supercomplexes Assembly and Respiratory Efficiency,” Cell 155, no. 1 (2013): 160–171.

[13] Y. Fannjiang, W. C. Cheng, S. J. Lee, et al., “Mitochondrial Fission Proteins Regulate Programmed Cell Death in Yeast,” Genes & Development 18, no. 22 (2004): 2785–2797.

[14] C. Bemeur, E. Beleac, S. Deschênes, et al., “Alterations in Mitochondrial Function in Fibroblasts From Patients With Leigh Syndrome French Canadian Type (LSFC),” FASEB Journal 26, no. 1 Supplement (2012): 586.

[15] A. B. Knott, G. Perkins, R. Schwarzenbacher, and E. Bossy-Wetzel, “Mitochondrial Fragmentation in Neurodegeneration,” Nature Reviews. Neuroscience 9, no. 7 (2008): 505–518.

[16] P. H. Willems, R. Rossignol, C. E. Dieteren, M. P. Murphy, and W. J. Koopman, “Redox Homeostasis and Mitochondrial Dynamics,” Cell Metabolism 22, no. 2 (2015): 207–218.

[17] M. J. Barsoum, H. Yuan, A. A. Gerencser, et al., “Nitric Oxide-Induced Mitochondrial Fission Is Regulated by Dynamin-Related GTPases in Neurons,” EMBO Journal 25, no. 16 (2006): 3900–3911.

[18] X. Qi, N. Qvit, Y. C. Su, and D. Mochly-Rosen, “A Novel Drp1 Inhibitor Diminishes Aberrant Mitochondrial Fission and Neurotoxicity,” Journal of Cell Science 126, no. Pt 3 (2013): 789–802.

[19] B. Schutz, J. Reimann, L. Dumitrescu-Ozimek, et al., “The Oral Antidiabetic Pioglitazone Protects From Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice,” Journal of Neuroscience 25, no. 34 (2005): 7805–7812.

[20] M. Pinto, N. Nissanka, S. Peralta, R. Brambilla, F. Diaz, and C. T. Moraes, “Pioglitazone Ameliorates the Phenotype of a Novel Parkinson's Disease Mouse Model by Reducing Neuroinflammation,” Molecular Neurodegeneration 2, no. 11 (2016): 25.

[21] L. Morato, J. Galino, M. Ruiz, et al., “Pioglitazone Halts Axonal Degeneration in a Mouse Model of X-Linked Adrenoleukodystrophy,” Brain 136, no. Pt 8 (2013): 2432–2443.

[22] I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith, “Pioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo,” Diabetes 54, no. 5 (2005): 1392–1399.

[23] G. Miglio, A. C. Rosa, L. Rattazzi, M. Collino, G. Lombardi, and R. Fantozzi, “PPARgamma Stimulation Promotes Mitochondrial Biogenesis and Prevents Glucose Deprivation-Induced Neuronal Cell Loss,” Neurochemistry International 55, no. 7 (2009): 496–504.

[24] N. K. LeBrasseur, M. Kelly, T. S. Tsao, et al., “Thiazolidinediones Can Rapidly Activate AMP-Activated Protein Kinase in Mammalian Tissues,” American Journal of Physiology. Endocrinology and Metabolism 291, no. 1 (2006): E175–E181.

[25] A. K. Saha, P. R. Avilucea, J. M. Ye, M. M. Assifi, E. W. Kraegen, and N. B. Ruderman, “Pioglitazone Treatment Activates AMP-Activated Protein Kinase in Rat Liver and Adipose Tissue In Vivo,” Biochemical and Biophysical Research Communications 314, no. 2 (2004): 580–585.

[26] M. P. Bhatt, Y. C. Lim, Y. M. Kim, and K. S. Ha, “C-Peptide Activates AMPKalpha and Prevents ROS-Mediated Mitochondrial Fission and Endothelial Apoptosis in Diabetes,” Diabetes 62, no. 11 (2013): 3851–3862.

[27] I. Amigo, F. M. da Cunha, M. F. Forni, et al., “Mitochondrial Form, Function and Signalling in Aging,” Biochemical Journal 473, no. 20 (2016): 3421–3449.

[28] J. Yang, S. Chen, F. Duan, et al., “Mitochondrial Cardiomyopathy: Molecular Epidemiology, Diagnosis, Models, and Therapeutic Management,” Cells 11, no. 21 (2022): 3511.

[29] Y. Zhang, L. Guo, S. Han, et al., “Adult Mesenchymal Stem Cell Ageing Interplays With Depressed Mitochondrial Ndufs6,” Cell Death & Disease 11, no. 12 (2020): 1075.

[30] S. C. Johnson, M. E. Yanos, E. B. Kayser, et al., “mTOR Inhibition Alleviates Mitochondrial Disease in a Mouse Model of Leigh Syndrome,” Science 342, no. 6165 (2013): 1524–1528.

[31] C. Perier, K. Tieu, C. Guegan, C. Guegan, and C. Caspersen, “Complex I Deficiency Primes Bax-Dependent Neuronal Apoptosis Through Mitochondrial Oxidative Damage,” Proceedings of the National Academy of Sciences of the United States of America 102, no. 52 (2005): 19126–19131.

[32] Z. Jin, W. Wei, M. Yang, Y. Du, and Y. Wan, “Mitochondrial Complex I Activity Suppresses Inflammation and Enhances Bone Resorption by Shifting Macrophage-Osteoclast Polarization,” Cell Metabolism 20, no. 3 (2014): 483–498.

[33] X. Guo, M. H. Disatnik, M. Monbureau, M. Shamloo, D. Mochly-Rosen, and X. Qi, “Inhibition of Mitochondrial Fragmentation Diminishes Huntington's Disease-Associated Neurodegeneration,” Journal of Clinical Investigation 123, no. 12 (2013): 5371–5388.

[34] T. M. Gupte, “Mitochondrial Fragmentation due to Inhibition of Fusion Increases Cyclin B Through Mitochondrial Superoxide Radicals,” PLoS One 10, no. 5 (2015): e0126829.

[35] A. Olichon, E. Guillou, C. Delettre, et al., “Mitochondrial Dynamics and Disease, OPA1,” Biochimica et Biophysica Acta 1763, no. 5–6 (2006): 500–509.

[36] U. Shirendeb, A. P. Reddy, M. Manczak, et al., “Abnormal Mitochondrial Dynamics, Mitochondrial Loss and Mutant Huntingtin Oligomers in Huntington's Disease: Implications for Selective Neuronal Damage,” Human Molecular Genetics 20, no. 7 (2011): 1438–1455.

[37] L. Sun, Q. Yuan, T. Xu, et al., “Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects Against Renal Fibrosis in 5/6 Nephrectomized Rats,” Frontiers in Pharmacology 8 (2017): 545.

[38] Q. Wang, M. Zhang, G. Torres, et al., “Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission,” Diabetes 66, no. 1 (2017): 193–205.

[39] R. J. Youle and A. M. van der Bliek, “Mitochondrial Fission, Fusion, and Stress,” Science 337, no. 6098 (2012): 1062–1065.

[40] D. Grahame Hardie, “Regulation of AMP-Activated Protein Kinase by Natural and Synthetic Activators,” Acta Pharmaceutica Sinica B 6, no. 1 (2016): 1–19.

[41] J. D. Wikstrom, T. Israeli, E. Bachar-Wikstrom, et al., “AMPK Regulates ER Morphology and Function in Stressed Pancreatic Beta-Cells via Phosphorylation of DRP1,” Molecular Endocrinology 27, no. 10 (2013): 1706–1723.

[42] A. Li, S. Zhang, J. Li, K. Liu, F. Huang, and B. Liu, “Metformin and Resveratrol Inhibit Drp1-Mediated Mitochondrial Fission and Prevent ER Stress-Associated NLRP3 Inflammasome Activation in the Adipose Tissue of Diabetic Mice,” Molecular and Cellular Endocrinology 434 (2016): 36–47.

[43] E. Q. Toyama, S. Herzig, J. Courchet, et al., “AMP-Activated Protein Kinase Mediates Mitochondrial Fission in Response to Energy Stress,” Science 351, no. 6270 (2016): 275–281.

[44] C. Cunningham, “Microglia and Neurodegeneration: The Role of Systemic Inflammation,” Glia 61, no. 1 (2013): 71–90.

[45] A. Dabrowska, J. L. Venero, R. Iwasawa, et al., “PGC-1alpha Controls Mitochondrial Biogenesis and Dynamics in Lead-Induced Neurotoxicity,” Aging (Albany NY) 7, no. 9 (2015): 629–647.

[46] K. Peng, L. Yang, J. Wang, et al., “The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1alpha Regulates Rotenone-Induced Dopaminergic Neurotoxicity,” Molecular Neurobiology 54, no. 5 (2017): 3783–3797.

[47] D. S. Currle, J. S. Hu, A. Kolski-Andreaco, and E. S. Monuki, “Culture of Mouse Neural Stem Cell Precursors,” Journal of Visualized Experiments 2 (2007): 152.

[48] C. T. Fang, H. H. Kuo, and L. H. Yih, “Mdivi-1 Induces Spindle Abnormalities and Augments Taxol Cytotoxicity in MDA-MB-231 Cells,” Cell Death Discovery 7, no. 1 (2021): 118.

[49] S. M. Shenouda, M. E. Widlansky, K. Chen, et al., “Altered Mitochondrial Dynamics Contributes to Endothelial Dysfunction in Diabetes Mellitus,” Circulation 124, no. 4 (2011): 444–453.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.